257 related articles for article (PubMed ID: 22901269)
1. Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells.
van Bekkum DW; Mikkers HM
Ann N Y Acad Sci; 2012 Aug; 1266():179-88. PubMed ID: 22901269
[TBL] [Abstract][Full Text] [Related]
2. The challenges and promises of blood engineered from human pluripotent stem cells.
Dravid GG; Crooks GM
Adv Drug Deliv Rev; 2011 Apr; 63(4-5):331-41. PubMed ID: 21232565
[TBL] [Abstract][Full Text] [Related]
3. Inability of human induced pluripotent stem cell-hematopoietic derivatives to downregulate microRNAs in vivo reveals a block in xenograft hematopoietic regeneration.
Risueño RM; Sachlos E; Lee JH; Lee JB; Hong SH; Szabo E; Bhatia M
Stem Cells; 2012 Feb; 30(2):131-9. PubMed ID: 22131151
[TBL] [Abstract][Full Text] [Related]
4. Stem cell transplantation for severe autoimmune diseases: progress and problems.
Marmont AM
Haematologica; 1998 Aug; 83(8):733-43. PubMed ID: 9793258
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
6. Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use.
Watt SM; Austin E; Armitage S
Methods Mol Biol; 2007; 368():237-59. PubMed ID: 18080475
[TBL] [Abstract][Full Text] [Related]
7. Prospects and challenges of reprogrammed cells in hematology and oncology.
Groß B; Pittermann E; Reinhardt D; Cantz T; Klusmann JH
Pediatr Hematol Oncol; 2012 Sep; 29(6):507-28. PubMed ID: 22857266
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
Ljungman P; Urbano-Ispizua A; Cavazzana-Calvo M; Demirer T; Dini G; Einsele H; Gratwohl A; Madrigal A; Niederwieser D; Passweg J; Rocha V; Saccardi R; Schouten H; Schmitz N; Socie G; Sureda A; Apperley J;
Bone Marrow Transplant; 2006 Mar; 37(5):439-49. PubMed ID: 16444286
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications.
Fløisand Y; Sioud M
Methods Mol Biol; 2010; 629():507-23. PubMed ID: 20387168
[TBL] [Abstract][Full Text] [Related]
11. [Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases].
Gratwohl A
Ther Umsch; 1996 Feb; 53(2):152-7. PubMed ID: 8629266
[TBL] [Abstract][Full Text] [Related]
12. How far are induced pluripotent stem cells from the clinic?
Li M; Chen M; Han W; Fu X
Ageing Res Rev; 2010 Jul; 9(3):257-64. PubMed ID: 20362696
[TBL] [Abstract][Full Text] [Related]
13. Generating autologous hematopoietic cells from human-induced pluripotent stem cells through ectopic expression of transcription factors.
Hwang Y; Broxmeyer HE; Lee MR
Curr Opin Hematol; 2017 Jul; 24(4):283-288. PubMed ID: 28383341
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
15. Promise and challenges of human iPSC-based hematologic disease modeling and treatment.
Ye Z; Chou BK; Cheng L
Int J Hematol; 2012 Jun; 95(6):601-9. PubMed ID: 22619021
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru JA; Jerabek L; Edwards CT; Weissman IL
Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications.
Das AK; Pal R
J Tissue Eng Regen Med; 2010 Aug; 4(6):413-21. PubMed ID: 20084623
[TBL] [Abstract][Full Text] [Related]
19. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
[TBL] [Abstract][Full Text] [Related]
20. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.
Porter DL; Hexner EO; Cooley S; Miller JS
Cancer Treat Res; 2009; 144():497-537. PubMed ID: 19779876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
